Source-grounded facts extracted from Eloxx Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Eloxx Pharmaceuticals, Inc. issued 2,500,000 shares of warrant to such investors.
“On May 27, 2026, such investors exchanged 2,500,000 shares of Common Stock issued in the Prefunded Warrant Exercise for prefunded warrants to purchase an equal number of shares of Common Stock”
Eloxx Pharmaceuticals, Inc. issued 2,500,000 shares of common stock to certain of the investors.
“On April 27, 2026, certain of the investors exercised pre-funded warrants to purchase an aggregate of 2,500,000 shares of Common Stock”
Eloxx Pharmaceuticals, Inc. issued 54,076,677 shares of warrant to the investors party thereto.
“the Company issued and sold prefunded warrants to purchase an aggregate of 54,076,677 shares of common stock”
Eloxx Pharmaceuticals, Inc.: Approved reverse stock split at a ratio between 1-for-2 and 1-for-20, with exact ratio determined by the Board; Board later approved a 1-for-11 reverse stock split and a reduction of authorized shares from 500,000,000 to 100,000,000 effective 5:00 p.m. ET on May 29, 2026 (effective 2026-05-29).
“On May 29, 2026, the Company filed with the Secretary of State of the State of Delaware (the "Delaware Secretary of State") a Certificate of Amendment to its Certificate of Incorporation (the "Certificate of Amendment") to effect the Reverse Stock Split and Authorized Share Reduction.”
Nina Kjellson was appointed as Director at Eloxx Pharmaceuticals, Inc..
“the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board”
Stephen W. Webster was appointed as Director at Eloxx Pharmaceuticals, Inc..
“the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board”
Eloxx Pharmaceuticals, Inc. shareholders approved Approve amendment to decrease authorized shares from 500,000,000 to 100,000,000 at the 2026-04-28 meeting.
“(iv) approved an amendment to the Certificate of Incorporation to decrease the number of authorized shares of Common Stock from 500,000,000 to 100,000,000, such decrease to be effected at such time and date as determined by the Board at any time on or prior to the one-year anniversary of the Record Date as determined by the Board in its sole discretion.”
Eloxx Pharmaceuticals, Inc. shareholders approved Approve reverse stock split of common stock at ratio between 1-for-2 and 1-for-20 at the 2026-04-28 meeting.
“(iii) approved amendments to the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”) to effect a reverse stock split of the Company’s Common Stock at a ratio ranging from any whole number between 1-for-2 to 1-for-20, with the exact ratio to be determined at the sole discretion of the Board at any time on or prior to the one-year anniversary of the Record Date;”
Eloxx Pharmaceuticals, Inc. shareholders approved Approve amendment and restatement of 2018 Equity Incentive Plan at the 2026-04-28 meeting.
“(ii) approved an amendment and restatement of the Original 2018 Plan, as amended by the First Amendment (the “Restated 2018 Plan”), in order to extend the period of time during which the Company may grant incentive stock options under the Restated 2018 Plan, further increase the ISO Limit, extend the evergreen provision and incorporate certain administrative and clarifying amendments;”
Eloxx Pharmaceuticals, Inc. shareholders approved Ratify first amendment to 2018 Equity Incentive Plan to increase shares to 20,000,000 and ISO limit to 30,000,000 at the 2026-04-28 meeting.
“(i) ratified and approved the first amendment (“First Amendment”) to the Company’s 2018 Equity Incentive Plan (the “Original 2018 Plan”) to increase the number of shares of Common Stock available for issuance of awards thereunder to 20,000,000 shares and increase the incentive stock option share limit (the “ISO Limit”) to 30,000,000 shares, which the Board of Directors of the Company (the “Board”) had previously approved and adopted;”
Eloxx Pharmaceuticals, Inc. entered into License Agreement with Almirall, S.A. valued at $3.0 million (effective 2024-03-11).
“entered into an exclusive license agreement with Almirall, S.A. (“Almirall”) covering the Company’s asset ZKN-013 (the “License Agreement”).”
Eloxx Pharmaceuticals, Inc. entered into Purchase Agreement with SD MF 4 LLC (effective 2024-01-09).
“On the Closing Date, the Company also entered into a securities purchase agreement (the “Purchase Agreement”) with the Assignee (the “Purchaser”)”
Eloxx Pharmaceuticals, Inc. amended Fifth Amendment to the Loan and Security Agreement with Hercules Capital, Inc., Hercules Capital IV, L.P., Zikani Therapeutics, Inc., Eloxx Pharmaceuticals Ltd. (effective 2024-01-09).
“On January 9, 2024 (the “Closing Date”), Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Fifth Amendment to the Loan and Security Agreement (the “Fifth Amendment”) by and among (i) Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent, and collateral agent, (ii) Hercules Capital IV, L.P., (collectively referred to as the “Lenders”), as a lender, (iii) the Company, as a borrower, (iv) Zikani Therapeutics, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, as a borrower (together with the Company, the “Borrower”), and (v) Eloxx Pharmaceuticals Ltd., an Israeli company and wholly-owned subsidiary of the Company (together with the Lenders and the Borrower, the “Parties”), which amended certain terms of the Loan and Security Agreement”
Tomer Kariv resigned as Chairman of the Board at Eloxx Pharmaceuticals, Inc..
“Mr. Tomer Kariv notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of his resignation from the Board and his position as Chairman of the Board and from the committee of the Board on which he serves.”
Eloxx Pharmaceuticals, Inc. amended credit facility of reducing the remaining outstanding principal of Term Loan Advances to $3.1 million with Hercules Capital, Inc., Hercules Capital IV, L.P..
“the Company has repaid $1.0 million of the outstanding principal (without incurring a prepayment premium), reducing the remaining outstanding principal of Term Loan Advances to $3.1 million. The foregoing description of the Fourth Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Fourth Amendment, a copy”
Eloxx Pharmaceuticals, Inc. amended Fourth Amendment with Hercules Capital, Inc. valued at $1.0 million (effective 2023-12-15).
“On December 15, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Fourth Amendment to the Loan and Security Agreement”
Eloxx Pharmaceuticals, Inc. reported third fiscal quarter ended September 30, 2023 results: net income $3.6 million, EPS $1.31 per share.
“For the three months ended September 30, 2023, we incurred a net loss of $3.6 million, or $1.31 per share”
Eloxx Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“October 12, 2023, Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), received a determination letter (the “Delisting Notification”) from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that Nasdaq will suspend trading in the Company’s common stock, par value $0.01 per share (the “Common Stock”), effective at the opening of trading on October 16, 2023, because the Company had not regained compliance with the Nasdaq Listing Rule 5550(b)(2) (the “Listing Rule”), which requires a listed company to have at least $3”
Eloxx Pharmaceuticals, Inc. entered into Purchase Agreement with a certain institutional investor (effective 2023-09-18).
“On September 18, 2023, Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”).”
Dr. Vijay Modur resigned as Head of Research and Development at Eloxx Pharmaceuticals, Inc..
“On September 15, 2023, Dr. Vijay Modur, Head of Research and Development of Eloxx Pharmaceuticals, Inc. (the “Company”), notified the Company of his resignation effective September 30, 2023.”
Eloxx Pharmaceuticals, Inc. reported financial results for the three months ended June 30, 2023.
“On August 14, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2023 and providing a business update.”
Eloxx Pharmaceuticals, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2023-06-22 meeting.
“Proposal 3 - Advisory vote on the compensation of the Company’s named executive officers.”
Eloxx Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-22 meeting.
“Proposal 2 - Ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023.”
Eloxx Pharmaceuticals, Inc. shareholders approved Election of five directors to hold office until the 2024 annual meeting at the 2023-06-22 meeting.
“Proposal 1 - Election of five (5) directors to hold office until the Company’s annual meeting of stockholders to be held in 2024 and until his or her respective successor is duly elected and qualified.”
Eloxx Pharmaceuticals, Inc. terminated SVB Sales Agreement with SVB Leerink LLC (effective 2023-05-24).
“nto a Sales Agreement (the “SVB Sales Agreement”) with SVB Leerink LLC (“Cowen”) to sell shares of the Company’s Common Stock with aggregate gross sales proceeds of up to $50 million, from time to time, through an “at the market” equity”
Eloxx Pharmaceuticals, Inc. entered into Oppenheimer Sales Agreement with Oppenheimer & Co. Inc. valued at aggregate gross sales proceeds of up to $50.0 million (effective 2023-05-24).
“On May 24, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Oppenheimer Sales Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”) pursuant to which the Company may offer and sell shares of its common stock, par value $0.01 per share (the “Common Stock”), having aggregate gross sales proceeds of up to $50.0 million”
Eloxx Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
“April 11, 2023, Eloxx Pharmaceuticals, Inc. (the “ Company ”) received a determination letter (the “ Letter ”) from the staff (the “ Staff ”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the Company has not regained compliance with Listing Rule 5550(b)(2) (the “ Minimum Market Value Requirement ”), requiring the Company to maintain a Market Value of Listed Securities of a minimum of $35 million, during the 180-day grace period previously granted to the Company. As previously disclosed, the Company was initially notified by the Staff on Octob”
Eloxx Pharmaceuticals, Inc. reported the three months ended December 31, 2022 results: net income net loss of $6.3 million, EPS $2.92 per share.
“For the three months ended December 31, 2022, we incurred a net loss of $6.3 million, or $2.92 per share”
Eloxx Pharmaceuticals, Inc. amended First Amendment to the Loan and Security Agreement with Hercules Capital, Inc. and Hercules Capital IV, L.P. (effective 2022-03-07).
“On March 7, 2022, Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the First Amendment to the Loan and Security Agreement (the “Amendment”) by and among (i) Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent, collateral agent, and a lender, (ii) Hercules Capital IV, L.P., (together with Hercules, the “Lenders”), as a lender, (iii) the Company, as a borrower, (iv) Zikani Therapeutics, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, as a borrower (together with the Company, the “Borrower”), and (v) Eloxx Pharmaceuticals Ltd., an Israeli company and wholly-owned subsidiary of the Company (together with the Lenders and the Borrower, the “Parties”), which amended certain terms of the Loan and Security Agreement, dated September 30, 20221, by and among the Parties (the “Loan Facility”).”
Eloxx Pharmaceuticals, Inc.: Implemented a 1-for-40 reverse stock split by filing a Certificate of Amendment to the Certificate of Incorporation (effective 2022-12-01).
“On December 1, 2022, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment (the “ Certificate of Amendment ”) with the Secretary of State of the State of Delaware to amend the Company’s Certificate of Incorporation to effect the Reverse Stock Split. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on December 1, 2022.”
Eloxx Pharmaceuticals, Inc. reported three months ended September 30, 2022 results: net income net loss of $7.5 million, or $0.09 per share, EPS $0.09 per share.
“For the three months ended September 30, 2022, we incurred a net loss of $7.5 million, or $0.09 per share, which included $0.7 million in stock-based compensation.”
Lindsay Androski was appointed as Director at Eloxx Pharmaceuticals, Inc..
“On June 30, 2022, the Board appointed Lindsay Androski to serve as a director on the Company’s Board to fill the remaining vacancy and as a member of the Board’s Audit Committee and Compensation Committee, in each case, effective as of the Effective Time.”
Gadi Veinrib resigned as Director at Eloxx Pharmaceuticals, Inc..
“On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.”
Rajesh Parekh resigned as Director at Eloxx Pharmaceuticals, Inc..
“On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.”
Zafrira Avnur resigned as Director at Eloxx Pharmaceuticals, Inc..
“On June 30, 2022, each of Zafrira Avnur, Rajesh Parekh and Gadi Veinrib notified the Board of their respective resignations from the Board and the respective committees of the Board on which they serve.”
Jasbir Seehra resigned as Director at Eloxx Pharmaceuticals, Inc..
“On June 28, 2022, each of Ran Nussbaum and Jasbir Seehra notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of their respective resignations from the Board and the respective committees of the Board on which they serve.”
Ran Nussbaum resigned as Director at Eloxx Pharmaceuticals, Inc..
“On June 28, 2022, each of Ran Nussbaum and Jasbir Seehra notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of their respective resignations from the Board and the respective committees of the Board on which they serve.”
Daniel Geffken was appointed as Principal Accounting Officer at Eloxx Pharmaceuticals, Inc..
“On August 17, 2021, the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed the Company’s Interim Chief Financial Officer, Daniel Geffken, to serve as the Company’s Principal Accounting Officer.”
Gary Rakers resigned as Executive Director, Finance & Accounting, Corporate Controller and Treasurer (Principal Accounting Officer) at Eloxx Pharmaceuticals, Inc..
“On July 14, 2021, Eloxx Pharmaceuticals, Inc. (the “Company”) was advised by Mr. Gary Rakers of his intention to resign as the Company’s Executive Director, Finance & Accounting, Corporate Conroller and Treasurer (Principal Accounting Officer) effective July 30, 2021.”
Neil Belloff departed as Chief Operating Officer and General Counsel at Eloxx Pharmaceuticals, Inc..
“Neil Belloff, Chief Operating Officer and General Counsel of the Company, agreed that Mr. Belloff would transition his responsibilities as Chief Operating Officer and General Counsel prior to his departure from the Company on or prior to August 25, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.